Online Webinar 2019 - 2 hrs Live Webinar The Influence of recent FDA and USP activities on Test Method Validation

Session Highlights
The following areas will be covered in this audio seminar.
The USP Stimulus article: Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification.
The three stages of test method validation:
Test Method Procedure Design (development and understanding)
Test Method Procedure Performance Qualification
Continued Test Method Procedure Performance Verification.
Analytical Target Profile
Test Method uncertainties
The Test Method Types
Test Method characteristics
Specificity
Accuracy
Precision
Linearity
Range
Limit of detection
Objective
This webinar will help the personnel in the Test Method Development Laboratory, Quality Control Laboratory and Quality Assurance understand the evolving practice of test method validation. The paradigm that test method validation is one experiment that is performed just before method transfer must be replaced with a proactive, lifecycle approach that includes the three stages of: Test Method Procedure Design (development and understanding), Test Method Procedure Performance Qualification and Continued Test Method Procedure Performance Verification. Further, It is important that the organization and the analyst understand the uncertainties of the test method, and therefore the reported results.
Overview
Since the requirement for test method validation appeared in the GMPs in 1978 the industry has considered that test method validation is a one-time event in the life of a test method. This concept was supported by interpretations of USP Validation of Compendial Methods first published in the 1980s and ICH Q2(R1), Validation of Analytical Procedures: Text and Methodology, which was finalized in 2005. The pharmaceutical industry, as all industries, is now taking a more proactive view of all processes and has adopted a lifecycle approach to process understanding and validation. The FDA issued a guidance on process validation, Process Validation: General Principles and Practices, in 2011 which advocated a lifecycle approach to process validation. The lifecycle concept was applied to test methods in recent USP stimulus article and there is now a move to apply the lifecycle approach to test methods. The life-cycle approach will put more emphasis on a clear definition of the intended use of a test method and the uncertainties associated with a test method.
In this webinar, we will discuss the lifecycle approach to test method validation and how it might impact the practice of method validation from the decision to develop a test method through to the discontinuation of the use of the method for the testing of a commercial product.
This ninety-minute webinar will begin with a review of the USP Stimulus Article, Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification along with the FDA 2011 Process Validation Guidance and a discussion of how these apply to and impact test method validation. Key elements of the discussion will be the three stages of test method validation, the importance of the Analytical Target Profile and an understanding of measurement uncertainty. The discussion will conclude with a review of the test method characteristics of accuracy, precision, linearity, range, specificity, limit of detection and limit of quantitation and the application of these characteristics through the test method lifecycle.
Who Will Benefit
Personnel who have responsibilities in laboratory operations, including Directors, Managers, Supervisors and line personnel.
QA, Quality Control and Method Development Directors, Managers and those involved with the development, transfer and use of test methods.
Personnel in analytical method development.
Quality Control Laboratory personnel
Validation specialists.
Speaker
John G. (Jerry) Lanese is an independent consultant with a focus on Quality Systems and the components of an effective Quality System. He received a BA and MS from Middlebury College and a Ph.D. in Analytical Chemistry from the University of Michigan and began his career teaching Analytical Chemistry in a small liberal arts college. Dr. Lanese moved from the academic environment to the pharmaceutical industry where he has managed Analytical Research, Quality Control and Quality Assurance functions.
In 1994 Dr. Lanese formed his own company, The Lanese Group, and since that time he has been a consultant in the area of quality system and cGMP compliance and has audited and consulted with small and large medical device and pharmaceutical companies, including companies under FDA Consent Decree, API and excipient manufacturers, electronic firms and other manufacturing organizations.
Dr. Lanese focuses on training. He lectures throughout the world and presents training in all formats (lectures, seminars and webinars) on a variety of topics related to Quality Systems, GMPs, APIs, training, laboratory operations, calibration, change control, deviations and product reviews for clients and seminar, webinar and conference providers. Jerry is a member of the Editorial Board of the Journal of GXP Compliance.